BioLineRx vs Ernexa Therapeutics
BLRX and ERNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BLRX and ERNA compare
Ernexa Therapeutics scores higher on the StockData Score (6 against 3 for BioLineRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BLRX | ERNA |
|---|---|---|
| Size and price | ||
| Market cap | – | $2.7M |
| Share price | $1.12 | $1.63 |
| Change, 1 year | −65.3% | −95.7% |
| Change, 5 years | −98.9% | −100.0% |
| Beta (5Y) | 1.56 | 2.80 |
| Employees | 20 | 5 |
| StockData Score | ||
| Total score | 3 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 0.8× |
| Growth | ||
| Revenue growth (TTM) | −95.9% | – |
| Profitability | ||
| Gross margin | 80.5% | – |
| Operating margin | −872% | – |
| FCF margin | −686% | – |
| Return on equity | – | −321% |
| Return on invested capital | −59.7% | – |
| Financial health | ||
| Debt / equity | 0.33 (better) | 0.00 |
| Interest coverage | −8.0× | – |
| Current ratio | 1.20 | 2.01 (better) |
| Altman Z-score | – | −62.69 |
| Piotroski F-score | – | 3 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.00% | – |
| Held by insiders | 0.39% | – |
| Insider net buying, 12 months | – | $2.0M |
Go deeper
- BLRX stock overview
- BLRX income statement
- BLRX valuation and score
- ERNA stock overview
- ERNA income statement
- ERNA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.